Nano Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 5.50 Cr
as on 12-08-2024
- Paid Up Capital ₹ 5.00 Cr
as on 12-08-2024
- Company Age 16 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 42.77 Cr
as on 12-08-2024
- Satisfied Charges ₹ 80.57 Cr
as on 12-08-2024
- Revenue 12.48%
(FY 2023)
- Profit -87.00%
(FY 2023)
- Ebitda 12.82%
(FY 2023)
- Net Worth 3.22%
(FY 2023)
- Total Assets 20.35%
(FY 2023)
About Nano Therapeutics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.50 Cr and a paid-up capital of Rs 5.00 Cr.
The company currently has active open charges totaling ₹42.77 Cr. The company has closed loans amounting to ₹80.57 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rajesh Vaishnav and Parth Vaishnav serve as directors at the Company.
- CIN/LLPIN
U33114GJ2008PTC082936
- Company No.
082936
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 May 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Nano Therapeutics Private Limited offer?
Nano Therapeutics Private Limited offers a wide range of products and services, including Surgical Accessories, Drug Eluting Stent, Biliary Stent, Diagnostic Medical Imaging Equipment, Medical Imaging Machine & Accessories, Cardiac Surgery Equipment, Coronary Stents, Infusion Syringes & Supplies, Catheter, Endoscopy & Laparoscopy instruments.
Who are the key members and board of directors at Nano Therapeutics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Vaishnav  | Managing Director | 08-Aug-2011 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Parth Vaishnav | Director | 25-Feb-2010 | Current |
Financial Performance of Nano Therapeutics.
Nano Therapeutics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.48% increase. The company also saw a substantial fall in profitability, with a 87% decrease in profit. The company's net worth moved up by a moderate rise of 3.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nano Therapeutics?
In 2023, Nano Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Transcath Therapeutics LlpActive 8 years 9 monthsRajesh Vaishnav and Parth Vaishnav are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 Feb 2023 | ₹3.00 Cr | Open |
Others Creation Date: 30 Nov 2022 | ₹5.00 Cr | Open |
Others Creation Date: 31 Mar 2022 | ₹34.77 Cr | Open |
How Many Employees Work at Nano Therapeutics?
Nano Therapeutics has a workforce of 170 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nano Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nano Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
